Sandoz

News

No news anytime soon on Sandoz sale, says Novartis

Novartis chief executive Vas Narasimhan has downplayed any chances of swift decision on the future of its generics business Sandoz, saying that a decision on the possible sale of the unit m

News

Novartis may have found a buyer for Sandoz; report

Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward.

News

Swiss socialists say government should buy Sandoz

Switzerland's Social Democratic Party has argued that the government should step in and acquire Novartis' generics unit Sandoz if the company decides to sell it, according to local press re

R&D

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum po...

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars.

News

Novartis looking into future of its Sandoz' generics busines...

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines.

R&D

Richard Francis on his Purespring plans: the pharmaphorum po...

In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this mont

No news anytime soon on Sandoz sale, says Novartis

Novartis may have found a buyer for Sandoz; report

Swiss socialists say government should buy Sandoz

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum po...

Novartis looking into future of its Sandoz' generics busines...

Richard Francis on his Purespring plans: the pharmaphorum po...

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Sandoz

Editor's Picks